Cyclacel Pharmaceuticals, Inc. will restate its financial statements due to material unintentional errors in accounting treatment, resulting in a decrease in net loss of $0.5 million in 2021 and an increase in total assets of $0.5 million in 2021, 2022, and the first two quarters of 2023.